Patent · US Active

Lyophilized formulations of tegavivint

US11602501B2 · kind B2 · utility

0Cited by
1References
22Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 4, 2021
Grant dateMar 14, 2023
Priority date—
Expiry dateOct 4, 2041

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K47/26
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Lyophilized formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.